Barclays PLC Buys 31,057 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO)

Barclays PLC boosted its stake in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) by 162.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 50,210 shares of the company’s stock after purchasing an additional 31,057 shares during the period. Barclays PLC owned approximately 0.15% of Lexeo Therapeutics worth $454,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in LXEO. Janus Henderson Group PLC increased its position in shares of Lexeo Therapeutics by 18.9% during the 3rd quarter. Janus Henderson Group PLC now owns 3,763,195 shares of the company’s stock valued at $33,997,000 after purchasing an additional 599,203 shares during the last quarter. Point72 Asset Management L.P. bought a new stake in Lexeo Therapeutics during the third quarter valued at approximately $3,348,000. Verition Fund Management LLC increased its holdings in Lexeo Therapeutics by 84.5% during the third quarter. Verition Fund Management LLC now owns 777,320 shares of the company’s stock valued at $7,027,000 after buying an additional 355,928 shares during the last quarter. Ikarian Capital LLC bought a new position in Lexeo Therapeutics in the third quarter worth approximately $2,325,000. Finally, State Street Corp boosted its stake in shares of Lexeo Therapeutics by 29.4% during the 3rd quarter. State Street Corp now owns 253,946 shares of the company’s stock worth $2,296,000 after acquiring an additional 57,674 shares during the last quarter. 60.67% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, CEO Richard Nolan Townsend sold 5,000 shares of the business’s stock in a transaction dated Thursday, October 10th. The stock was sold at an average price of $8.10, for a total value of $40,500.00. Following the sale, the chief executive officer now directly owns 120,695 shares in the company, valued at approximately $977,629.50. The trade was a 3.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold 10,000 shares of company stock worth $80,550 in the last three months. 4.50% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on LXEO shares. Leerink Partners decreased their target price on Lexeo Therapeutics from $20.00 to $19.00 and set an “outperform” rating on the stock in a report on Wednesday, November 13th. HC Wainwright raised their price objective on Lexeo Therapeutics from $21.00 to $23.00 and gave the stock a “buy” rating in a research note on Thursday, November 14th. Finally, Chardan Capital boosted their price objective on Lexeo Therapeutics from $23.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Lexeo Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $23.80.

Lexeo Therapeutics Stock Performance

NASDAQ LXEO opened at $7.29 on Friday. The business has a 50-day moving average price of $7.31 and a 200-day moving average price of $10.21. The firm has a market cap of $241.05 million and a price-to-earnings ratio of -2.31. Lexeo Therapeutics, Inc. has a twelve month low of $5.77 and a twelve month high of $22.33. The company has a quick ratio of 5.95, a current ratio of 5.95 and a debt-to-equity ratio of 0.01.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.